31 min listen
First Topical Gene Therapy + Bausch + Lomb's First Prescription Med for Dry Eye
First Topical Gene Therapy + Bausch + Lomb's First Prescription Med for Dry Eye
ratings:
Length:
26 minutes
Released:
May 31, 2023
Format:
Podcast episode
Description
In this episode, Ayesha talked about the FDA approval of the first topical gene therapy for the treatment of a rare skin condition. Krystal Biotech’s Vyjuvek is a topical gene therapy that has been approved for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). It’s the first treatment for the rare disease. Hear more about DEB and Vyjuvek in this episode.Ayesha and the team also discussed the FDA approval of Bausch + Lomb’s first prescription drug for the treatment of dry eye disease. The drug, called Miebo, is also the first treatment that targets tear evaporation, which is a leading cause of dry eye disease. Hear more about the drug and its approval in the show.Read the full articles here:Vyjuvek Gets FDA Nod as First Topical Gene Therapy for Rare Skin DiseaseMiebo Approved as First Dry Eye Disease Treatment to Target Tear EvaporationFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Released:
May 31, 2023
Format:
Podcast episode
Titles in the series (100)
First FDA-Approved Treatment for Chronic Yeast Infection + Eli Lilly Obesity Drug Shows Promise in Trials by Xtalks Life Science Podcast